Lost password ?
<< Back to Equity Research
Dallah Healthcare
DALLAH WORTHY BUT EXPENSIVE
Oct 24 - Dallah Healthcare (Sell, Saudi Arabia) has been in a euphoric rally since more than 18 months. Our successive target upgrades during the past months have not succeeded to catch the share price which ...
Executive summary
Conflict of Interest
Pages 38
Language English
Publish on October 24, 2022
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 08 AM
Mouwasat Medical
Target pushed up by strong results
Mar 26 AM
Dallah Healthcare
Target boosted by a strong outlook
Mar 26 AM
Mouwasat Medical
Mouwasat Medical increases its net profit by 10%
Mar 15 AM
Dallah Healthcare
A slightly-weaker-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ